戻る Agendas
Session 0701 New Trend/Technology in Biologic Development
Session Chair(s)
Chengbin Wu
Chief Scientific Officer, President of R&D
Shanghai CP Guojian Pharmaceuticals Co. Ltd., China
Speaker(s)
Bispecific Antibody TCell Engager for Cancer Immunotherapy
Mingqiang Zhang
Amgen BioPharmaceutical R&D (Shanghai) Co., Ltd, China
General Manager, Corporate VP of R&D
Antibody Drug Discovery Develop Critical Assays for Novel Antibody Drugs
Kang Li
BeiGene, China
Head of Biologics
Antibody Drug Discovery Develop Critical Assays for Novel Antibody Drugs
Peter Luo
Adagene Inc., China
Co-founder and Chief Executive Officer